Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (Nasdaq:VCYT) announced the U.S. commercial launch of its Prosigna Breast Risk of Recurrence (ROR) test for early-stage HR+ breast cancer, available to order starting June 8, 2026.
The genomic test estimates a patient’s 10-year distant recurrence risk and, according to Veracyte, predicts chemotherapy benefit, helping personalize treatment decisions. The company reports broad commercial payer coverage and financial assistance options.
Veracyte (Nasdaq:VCYT) reported ENZAMET Phase III data at ASCO 2026 showing its Decipher Prostate genomic test can identify which men with metastatic prostate cancer benefit from adding docetaxel to ADT plus enzalutamide.
In 634 patients (median follow-up 5.6 years), a significant treatment-by-biomarker interaction (p=0.043) provided Level 1B evidence. High Decipher scores (>0.85) with high-volume disease saw improved survival with triplet therapy, while low-score patients showed no added chemotherapy benefit. Additional pooled NRG/RTOG data in high-risk localized disease showed Decipher improved prognostic accuracy and reclassified about 1 in 4 patients, indicating more may benefit from ARPI-based treatment intensification.
Veracyte (Nasdaq:VCYT) reported Phase III OPTIMA trial results showing its Prosigna Breast Risk of Recurrence test can guide adjuvant chemotherapy decisions in early-stage, ER-positive, HER2-negative breast cancer.
The 4,429-patient study found 68% of clinically high-risk, node-positive patients could avoid chemotherapy with 5-year cancer-free survival of 93.7% versus 94.9% with chemotherapy.
Veracyte (Nasdaq:VCYT) will host an investor conference call and webcast on June 1, 2026 at 8:30 a.m. ET to discuss data from two phase III clinical trials using its Prosigna Breast and Decipher Prostate tests, including results from the OPTIMA and ENZAMET trials.
Professor Iain Macpherson will join the discussion. The live and replay webcasts will be accessible via Veracyte’s investor relations website.
Veracyte (NASDAQ:VCYT) will present new data from phase III OPTIMA and ENZAMET trials at the 2026 ASCO Annual Meeting. These studies evaluate how Prosigna Breast and Decipher Prostate genomic tests can guide chemotherapy and treatment intensification decisions in early breast cancer and metastatic prostate cancer.
Veracyte (Nasdaq:VCYT) will participate in two upcoming investor conferences. Management presents at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and at the Jefferies Global Healthcare Conference in New York on June 4, 2026.
Both events feature live and replay webcasts via Veracyte’s investor relations site.
Veracyte (Nasdaq:VCYT) received Medicare MolDX coverage for its TrueMRD Monitoring Test in muscle-invasive bladder cancer (MIBC). The test is covered for recurrence monitoring after curative-intent treatment and becomes orderable on June 1, 2026, marking Veracyte’s first commercial molecular residual disease offering.
According to Veracyte, the whole-genome, tumor-informed TrueMRD platform showed a median detection of recurrence 131 days earlier than imaging in the PAGER study of 112 MIBC patients. The platform is also used in ongoing TOMBOLA and NEO-BLAST trials, supporting its role in evolving MIBC treatment and surveillance strategies.
Veracyte (Nasdaq: VCYT) reported Q1 2026 results: total revenue $139.1M (+21% YoY) and testing revenue $135.1M (+26% YoY). Decipher revenue grew 30% to $86.5M; Afirma grew 21% to $46.4M. GAAP net income was $28.7M and adjusted EBITDA was $42.8M (30.8% of revenue). Cash from operations was $35.2M; cash and short-term investments totaled $439.1M as of March 31, 2026. Company raised 2026 revenue guidance to $582M–$592M and testing revenue to $570M–$580M, and raised adjusted EBITDA margin guidance to >26%.
Veracyte (Nasdaq: VCYT) announced that more than 15 studies on the Decipher portfolio will be presented at the AUA 2026 meeting (May 15–18, Washington, D.C.).
Highlights include Decipher Bladder molecular subtyping data linking subtypes to outcomes and responses to neoadjuvant chemo‑immunotherapy, and national‑scale Decipher Prostate real‑world analyses powered by the Decipher GRID database with more than a decade of data. Veracyte will be at booth #3405.
Veracyte (Nasdaq: VCYT) will release first quarter 2026 financial results after market close on May 5, 2026.
Management will host a conference call and live webcast at 4:30 p.m. Eastern Time on May 5, 2026 to discuss results and provide a business update; a replay will be available on the company’s investor website.